Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies
Research on the formation of new blood vessels (angiogenesis) in general and vascular endothelial growth factor (VEGF) in particular is a major focus in biomedicine and has led to the clinical approval of the monoclonal anti- VEGF antibody bevazicumab; and the second-generation multitargeted recepto...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2011
|
| In: |
Current cancer drug targets
Year: 2011, Volume: 11, Issue: 9, Pages: 1005-1024 |
| ISSN: | 1873-5576 |
| DOI: | 10.2174/156800911798073113 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2174/156800911798073113
|
| Author Notes: | K. Podar and K.C. Anderson |
| Summary: | Research on the formation of new blood vessels (angiogenesis) in general and vascular endothelial growth factor (VEGF) in particular is a major focus in biomedicine and has led to the clinical approval of the monoclonal anti- VEGF antibody bevazicumab; and the second-generation multitargeted receptor kinase inhibitors (RTKIs) sorafenib, sunitinib, and pazopanib. Although these agents show significant preclinical and clinical anti-cancer activity, they prolong overall survival of cancer patients for only months, followed by a restoration of tumor growth and progression. Therefore, there is a clear need to increase our understanding of tumor angiogenesis and the development of resistance. In this review we discuss up-to-date knowledge on mechanisms of tumor angiogenesis, and summarize preclinical and clinical data on existing and potential future anti-angiogenic agents and treatment strategies for Multiple Myeloma (MM) and other hematologic and solid malignancies. |
|---|---|
| Item Description: | Gesehen am 23.12.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1873-5576 |
| DOI: | 10.2174/156800911798073113 |